Eagle Pharmaceuticals (EGRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2022 | 12-2021 | 12-2020 | 12-2019 | 12-2018 | |
| Sales | 316,610 | 171,546 | 187,802 | 195,892 | 213,312 |
| Cost of Goods | 94,936 | 42,180 | 45,465 | 60,897 | 61,916 |
| Gross Profit | 221,674 | 129,366 | 142,337 | 134,995 | 151,396 |
| Operating Expenses | 141,650 | 126,777 | 109,848 | 114,077 | 115,696 |
| Operating Income | 80,960 | 2,769 | 32,954 | 21,815 | 36,616 |
| Interest Expense | 4,045 | 1,635 | 2,577 | 2,686 | 2,736 |
| Other Income | -15,482 | -5,682 | -7,700 | 2,869 | 158 |
| Pre-tax Income | 61,433 | -4,548 | 22,677 | 21,998 | 34,038 |
| Income Tax | 25,791 | 4,079 | 10,688 | 7,685 | 2,135 |
| Net Income Continuous | 35,642 | -8,627 | 11,989 | 14,313 | 31,903 |
| Net Income | $35,642 | $-8,627 | $11,989 | $14,313 | $31,903 |
| EPS Basic Total Ops | 2.76 | -0.66 | 0.89 | 1.04 | 2.16 |
| EPS Basic Continuous Ops | 2.76 | -0.66 | 0.89 | 1.04 | 2.16 |
| EPS Diluted Total Ops | 2.73 | -0.66 | 0.87 | 1.01 | 2.09 |
| EPS Diluted Continuous Ops | 2.73 | -0.66 | 0.87 | 1.01 | 2.09 |
| EPS Diluted Before Non-Recurring Items | 2.73 | -0.66 | 0.87 | 1.38 | 2.09 |
| EBITDA(a) | $94,696 | $8,047 | $38,139 | $26,946 | $40,662 |